Holen Sie sich die Stockscreener-App
78.11
1.06%
-0.84
Handel nachbörslich:
78.73
0.62
+0.79%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt NVO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$78.95
Offen:
$78.88
24-Stunden-Volumen:
7.42M
Relative Volume:
0.88
Marktkapitalisierung:
$346.73B
Einnahmen:
$42.09B
Nettoeinkommen (Verlust:
$14.65B
KGV:
23.79
EPS:
3.2833
Netto-Cashflow:
$10.11B
1W Leistung:
-10.73%
1M Leistung:
-6.72%
6M Leistung:
-42.24%
1J Leistung:
-40.48%
1-Tages-Spanne:
$77.00
$79.27
1-Wochen-Bereich:
$77.00
$91.90
52-Wochen-Spanne:
$77.00
$148.15
Novo Nordisk Adr Stock (NVO) Company Profile
Vergleichen Sie NVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
78.11 | 346.73B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
LLY
Lilly Eli Co
|
824.06 | 783.19B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
213.59 | 377.06B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
165.86 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
94.73 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Neutral |
| 2023-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Eingeleitet | Argus | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2022-07-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-06-27 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-04-25 | Hochstufung | Cowen | Market Perform → Outperform |
| 2022-04-12 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Herabstufung | Liberum | Hold → Sell |
| 2021-12-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-07-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-05-11 | Herabstufung | UBS | Buy → Neutral |
| 2020-05-04 | Eingeleitet | Cowen | Market Perform |
| 2020-03-16 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-11-18 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-30 | Herabstufung | Jefferies | Hold → Underperform |
| 2019-06-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2017-12-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
Alle ansehen
Novo Nordisk Adr Aktie (NVO) Neueste Nachrichten
NVO Shareholders Have an Opportunity to Lead the Class Action Against Novo Nordisk A/S – Contact Shareholder Rights Law Firm Robbins LLP for Information - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/SNVO - Finansavisen
Novo Nordisk AS (NVO) Stock Price, Trades & News - GuruFocus.com
Novo Nordisk A/S Sponsored ADR Class B to Host Earnings Call - ACCESS Newswire
NVO Stock Quote Price and Forecast - CNN
Repare Surprises On Earnings; California Resources Falls Short - Evrim Ağacı
Why weight-loss drugs are the top target of Medicare price negotiations - Equities News
Are Investors Inclined To Sell Their Novo Nordisk ADR (NYSE: NVO) Holdings? - Stocks Register
The Attractiveness of Investing In Novo Nordisk ADR (NVO) is Growing - Knox Daily
Ero Copper Corp (ERO) gets rating Initiated from Goldman - Knox Daily
Itau Unibanco Holding S.A. ADR (ITUB) Stock Records -5.92% Quarterly Movement - The News Heater
Novo Nordisk ADR (NVO) Shares Decline Despite Market Challenges - The News Heater
A Stock Analysis Of Novo Nordisk ADR’s (NVO) - Stocks Register
Examining Novo Nordisk ADR (NVO) more closely is necessary - US Post News
NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up - MSN
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth - Morningstar
Novo Nordisk ADR [NVO] Is Currently -0.04 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Novo Nordisk Stock Rises After Earnings. It Expects Good News From the FDA. - Barron's
Novo Nordisk Shares Surge on Strong Sales of Wegovy, Despite Slight Earnings Miss – market - HPBL
Novo Nordisk Stock Up After Earnings. Weight-Loss Drugmaker Sees Slower Growth. - Barron's
Novo Nordisk ADR earnings beat by $5.46, revenue topped estimates - Investing.com Nigeria
Finanzdaten der Novo Nordisk Adr-Aktie (NVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):